

# Ernst Lengyel

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1736472/ernst-lengyel-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145  
papers

16,106  
citations

55  
h-index

126  
g-index

182  
ext. papers

18,907  
ext. citations

8.6  
avg, IF

6.67  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 145 | The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. <i>Genes and Development</i> , <b>2008</b> , 22, 894-907  | 12.6 | 1780      |
| 144 | Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. <i>Nature Medicine</i> , <b>2011</b> , 17, 1498-503  | 50.5 | 1295      |
| 143 | Ovarian cancer development and metastasis. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 1053-64   | 5.8  | 1010      |
| 142 | Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , <b>2011</b> , 11, 719-25   | 31.3 | 893       |
| 141 | Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , <b>2015</b> , 521, 489-94  | 50.4 | 890       |
| 140 | Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , <b>2015</b> , 15, 668-79  | 31.3 | 581       |
| 139 | Adipose tissue and adipocytes support tumorigenesis and metastasis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2013</b> , 1831, 1533-41  | 5    | 427       |
| 138 | Let-7 expression defines two differentiation stages of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 11400-5   | 11.5 | 397       |
| 137 | mA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. <i>Nature Cell Biology</i> , <b>2018</b> , 20, 1074-1083   | 23.4 | 358       |
| 136 | Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. <i>Oncogene</i> , <b>2000</b> , 19, 3013-20  | 9.2  | 306       |
| 135 | Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 10672-80 | 5.4  | 291       |
| 134 | CD95 promotes tumour growth. <i>Nature</i> , <b>2010</b> , 465, 492-6  | 50.4 | 286       |
| 133 | Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. <i>Cancer Research</i> , <b>2008</b> , 68, 2329-39  | 10.1 | 282       |
| 132 | The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 1367-79   | 15.9 | 261       |
| 131 | MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1100-8   | 24.4 | 254       |
| 130 | Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. <i>Oncogene</i> , <b>1997</b> , 14, 1481-93   | 9.2  | 219       |
| 129 | c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. <i>Cancer Research</i> , <b>2007</b> , 67, 1670-9   | 10.1 | 217       |

|     |  |      |     |
|-----|--|------|-----|
| 128 | Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, 1356-65  | 4    | 205 |
| 127 | C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. <i>International Journal of Cancer</i> , <b>2005</b> , 113, 678-82   | 7.5  | 203 |
| 126 | Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. <i>Oncogene</i> , <b>2018</b> , 37, 2285-2301  | 9.2  | 197 |
| 125 | Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. <i>International Journal of Cancer</i> , <b>2007</b> , 121, 1463-72       | 7.5  | 197 |
| 124 | Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. <i>Cell Cycle</i> , <b>2007</b> , 6, 2585-90  | 4.7  | 197 |
| 123 | Ligand-independent activation of c-Met by fibronectin and $\alpha 5 \beta 1$ -integrin regulates ovarian cancer invasion and metastasis. <i>Oncogene</i> , <b>2011</b> , 30, 1566-76   | 9.2  | 193 |
| 122 | Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 4614-28   | 15.9 | 189 |
| 121 | Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. <i>Trends in Cancer</i> , <b>2018</b> , 4, 374-384   | 12.5 | 168 |
| 120 | Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. <i>Nature</i> , <b>2019</b> , 569, 723-728   | 50.4 | 155 |
| 119 | Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. <i>Cell Metabolism</i> , <b>2016</b> , 24, 728-739  | 24.6 | 152 |
| 118 | Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. <i>Oncogene</i> , <b>2004</b> , 23, 9369-80  | 9.2  | 146 |
| 117 | Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 176-194   | 16.6 | 146 |
| 116 | Epithelial ovarian cancer experimental models. <i>Oncogene</i> , <b>2014</b> , 33, 3619-33   | 9.2  | 140 |
| 115 | Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 78-92   | 6.6  | 132 |
| 114 | Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. <i>Obstetrics and Gynecology</i> , <b>2012</b> , 119, 61-7   | 4.9  | 129 |
| 113 | A phase II, single-arm study of the anti- $\alpha 5 \beta 1$ integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. <i>Gynecologic Oncology</i> , <b>2011</b> , 121, 273-9 | 4.9  | 119 |
| 112 | Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. <i>Nature Communications</i> , <b>2015</b> , 6, 6220   | 17.4 | 118 |
| 111 | Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. <i>Cell Metabolism</i> , <b>2019</b> , 29, 141-155.e9  | 24.6 | 117 |

|     |   |      |     |
|-----|---|------|-----|
| 110 | Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1342-1351   | 24.4 | 116 |
| 109 | Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 1787-97  | 7.5  | 115 |
| 108 | MMP-2 functions as an early response protein in ovarian cancer metastasis. <i>Cell Cycle</i> , <b>2009</b> , 8, 683-8   | 4.7  | 95  |
| 107 | HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 3603-17  | 15.9 | 89  |
| 106 | Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. <i>Gynecologic Oncology</i> , <b>2001</b> , 82, 291-8   | 4.9  | 89  |
| 105 | Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4042-51                   | 12.9 | 87  |
| 104 | The urokinase plasminogen activator system as a novel target for tumour therapy. <i>Fibrinolysis and Proteolysis</i> , <b>2000</b> , 14, 114-132  |      | 86  |
| 103 | Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. <i>American Journal of Obstetrics and Gynecology</i> , <b>2015</b> , 212, 479.e1-479.e10  | 6.4  | 78  |
| 102 | miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin $\beta$ expression. <i>American Journal of Pathology</i> , <b>2013</b> , 182, 1876-89  | 5.8  | 74  |
| 101 | Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 680-6   | 12.9 | 69  |
| 100 | Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 16377-86   | 5.4  | 68  |
| 99  | Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. <i>Cell</i> , <b>2018</b> , 175, 159-170.e16  | 56.2 | 67  |
| 98  | Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. <i>Cancer Treatment and Research</i> , <b>2009</b> , 149, 335-51            | 3.5  | 66  |
| 97  | In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. <i>Melanoma Research</i> , <b>1998</b> , 8, 211-9   | 3.3  | 62  |
| 96  | Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 459-71   | 12.9 | 61  |
| 95  | Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. <i>Oncogene</i> , <b>1997</b> , 14, 2563-73 | 9.2  | 61  |
| 94  | The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 11342-56  | 3.3  | 59  |
| 93  | An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. <i>Neoplasia</i> , <b>2010</b> , 12, 1-10   | 6.4  | 58  |

|    |  |      |    |
|----|--|------|----|
| 92 | {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. <i>American Journal of Pathology</i> , <b>2009</b> , 175, 2184-96 | 5.8  | 57 |
| 91 | Old drug, new trick: repurposing metformin for gynecologic cancers?. <i>Gynecologic Oncology</i> , <b>2014</b> , 135, 614-21   | 4.9  | 55 |
| 90 | Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 23176-84          | 5.4  | 54 |
| 89 | Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. <i>Communications Biology</i> , <b>2019</b> , 2, 386                                       | 6.7  | 54 |
| 88 | Who are the long-term survivors of high grade serous ovarian cancer?. <i>Gynecologic Oncology</i> , <b>2018</b> , 148, 204-212   | 4.9  | 54 |
| 87 | The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. <i>Cancer Discovery</i> , <b>2011</b> , 1, 100-2  | 24.4 | 53 |
| 86 | Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 2822-34                            | 5.4  | 53 |
| 85 | Tyrosine kinase mutations in human cancer. <i>Current Molecular Medicine</i> , <b>2007</b> , 7, 77-84  | 2.5  | 53 |
| 84 | Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 23007-12                                     | 5.4  | 52 |
| 83 | A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis. <i>Journal of Pathology</i> , <b>2020</b> , 251, 100-112   | 9.4  | 50 |
| 82 | Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 26340-8   | 5.4  | 49 |
| 81 | Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 2282-2293                                      | 6.1  | 46 |
| 80 | Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5357-5367  | 12.9 | 45 |
| 79 | Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. <i>American Journal of Pathology</i> , <b>2014</b> , 184, 271-81  | 5.8  | 45 |
| 78 | beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. <i>Molecular and Cellular Biology</i> , <b>2001</b> , 21, 2118-32    | 4.8  | 45 |
| 77 | Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. <i>Cancer Research</i> , <b>2020</b> , 80, 1748-1761   | 10.1 | 44 |
| 76 | Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 656-62  | 4.9  | 43 |
| 75 | Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. <i>Journal of Cellular Biochemistry</i> , <b>1996</b> , 61, 430-43                            | 4.7  | 42 |

|    |   |      |    |
|----|---|------|----|
| 74 | Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. <i>Endocrinology</i> , <b>2009</b> , 150, 4306-15   | 4.8  | 41 |
| 73 | Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. <i>Histopathology</i> , <b>2007</b> , 51, 54-62   | 7.3  | 41 |
| 72 | Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2008</b> , 111, 173-8  | 4.9  | 39 |
| 71 | PDGFR-alpha as a potential therapeutic target in uterine sarcomas. <i>Gynecologic Oncology</i> , <b>2007</b> , 104, 524-8   | 4.9  | 39 |
| 70 | Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e104521  | 3.7  | 35 |
| 69 | A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2009</b> , 17, 57-67   | 1.9  | 34 |
| 68 | UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. <i>Journal of Investigative Dermatology</i> , <b>1999</b> , 113, 69-76   | 4.3  | 34 |
| 67 | SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 870-881  | 6.6  | 32 |
| 66 | The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. <i>Fertility and Sterility</i> , <b>2010</b> , 94, 1212-1217  | 4.8  | 32 |
| 65 | Gastrin induces expression and promoter activity of the vesicular monoamine transporter subtype 2. <i>Endocrinology</i> , <b>2001</b> , 142, 3663-72  | 4.8  | 32 |
| 64 | Unsaturated Fatty Acids Maintain Cancer Cell Stemness. <i>Cell Stem Cell</i> , <b>2017</b> , 20, 291-292  | 18   | 31 |
| 63 | Three-dimensional modeling of ovarian cancer. <i>Advanced Drug Delivery Reviews</i> , <b>2014</b> , 79-80, 184-92   | 18.5 | 31 |
| 62 | Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. <i>Molecular Cancer Research</i> , <b>2007</b> , 5, 485-96  | 6.6  | 30 |
| 61 | Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 2628-39  | 6.1  | 29 |
| 60 | Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 23548-60  | 3.3  | 29 |
| 59 | Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. <i>Cardiovascular Research</i> , <b>2001</b> , 49, 189-99 | 9.9  | 27 |
| 58 | Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 8538-48              | 12.9 | 25 |
| 57 | Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. <i>Obstetrics and Gynecology</i> , <b>2021</b> , 137, 108-121  | 4.9  | 25 |

|    |   |       |    |
|----|---|-------|----|
| 56 | A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. <i>Biomaterials</i> , <b>2019</b> , 190-191, 63-75   | 15.6  | 25 |
| 55 | An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. <i>Nature Communications</i> , <b>2017</b> , 8, 1775   | 17.4  | 24 |
| 54 | FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas. <i>Pediatric and Developmental Pathology</i> , <b>2011</b> , 14, 391-5   | 2.2   | 24 |
| 53 | Patterns and utility of routine surveillance in high grade endometrial cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 137, 485-9   | 4.9   | 23 |
| 52 | New Roles for Glycogen in Tumor Progression. <i>Trends in Cancer</i> , <b>2019</b> , 5, 396-399   | 12.5  | 22 |
| 51 | Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>1995</b> , 1268, 65-72 | 4.9   | 22 |
| 50 | Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. <i>Cell</i> , <b>2021</b> , 184, 3163-3173   | 36.21 | 21 |
| 49 | A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. <i>SLAS Discovery</i> , <b>2017</b> , 22, 494-506   | 3.4   | 20 |
| 48 | High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2017</b> , 146, 153-160  | 4.9   | 18 |
| 47 | The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. <i>Molecular and Cellular Endocrinology</i> , <b>2010</b> , 317, 112-9                              | 4.4   | 17 |
| 46 | Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 3632-44  | 5.6   | 17 |
| 45 | Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia. <i>Obstetrics and Gynecology</i> , <b>2000</b> , 96, 582-7  | 4.9   | 17 |
| 44 | Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. <i>Gynecologic Oncology</i> , <b>2012</b> , 127, 316-20   | 4.9   | 16 |
| 43 | Role of beta(3)-endoneurin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor. <i>Journal of Cell Science</i> , <b>2002</b> , 115, 3879-88                                      | 5.3   | 16 |
| 42 | Cytological diagnosis of zosteriform skin metastases in undiagnosed breast carcinoma. <i>British Journal of Dermatology</i> , <b>1996</b> , 135, 502-3  | 4     | 16 |
| 41 | RADAR: differential analysis of MeRIP-seq data with a random effect model. <i>Genome Biology</i> , <b>2019</b> , 20, 294  | 18.3  | 16 |
| 40 | Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. <i>Cancer Prevention Research</i> , <b>2017</b> , 10, 255-266                              | 3.2   | 15 |
| 39 | Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 405-415   | 4.9   | 15 |

|    |   |      |    |
|----|---|------|----|
| 38 | The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 228-234                            | 4.9  | 14 |
| 37 | The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. <i>Trends in Cancer</i> , <b>2018</b> , 4, 517-519  | 12.5 | 14 |
| 36 | Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. <i>Gynecologic Oncology</i> , <b>2008</b> , 111, 537-549                 | 4.9  | 13 |
| 35 | Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. <i>Cancer Prevention Research</i> , <b>2009</b> , 2, 792-9                                   | 3.2  | 12 |
| 34 | Deconstructing tumor heterogeneity: the stromal perspective. <i>Oncotarget</i> , <b>2020</b> , 11, 3621-3632  | 3.3  | 12 |
| 33 | Mesothelial Cell HIF1 $\alpha$ Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. <i>Cell Reports</i> , <b>2019</b> , 29, 4086-4098.e6  | 10.6 | 12 |
| 32 | Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 52-62                                     | 6.1  | 12 |
| 31 | Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. <i>Scientific Reports</i> , <b>2019</b> , 9, 5195  | 4.9  | 10 |
| 30 | Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. <i>Gynecologic Oncology</i> , <b>2013</b> , 129, 120-3  | 4.9  | 10 |
| 29 | Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , <b>2004</b> , 94, 204-7  | 4.9  | 10 |
| 28 | The effects of 17 $\beta$ -estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. <i>Gynecologic Oncology</i> , <b>2012</b> , 124, 134-41  | 4.9  | 9  |
| 27 | Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women. <i>Journal of Women's Health</i> , <b>2021</b> , 30, 502-513 <sup>3</sup> |      | 9  |
| 26 | The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. <i>Gynecologic Oncology</i> , <b>2011</b> , 121, 218-23   | 4.9  | 8  |
| 25 | Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. <i>Cancer Research</i> , <b>2017</b> , 77, 1684-1696                                   | 10.1 | 7  |
| 24 | Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. <i>Journal of Visualized Experiments</i> , <b>2015</b> , e53541  | 1.6  | 7  |
| 23 | Keratin expression reveals mosaic differentiation in vaginal epithelium. <i>American Journal of Obstetrics and Gynecology</i> , <b>1993</b> , 169, 1603-7   | 6.4  | 7  |
| 22 | Die Physiologie der Zervixreifung. <i>Der Gynakologe</i> , <b>2001</b> , 34, 708-714  | 0.1  | 6  |
| 21 | JNK and p38MAPK are activated during graft reperfusion and not during cold storage in rat liver transplantation. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 931-2   | 1.1  | 6  |



|    |  |      |   |
|----|--|------|---|
| 20 | Ras regulation of urokinase-type plasminogen activator. <i>Methods in Enzymology</i> , <b>2001</b> , 333, 105-16   | 1.7  | 5 |
| 19 | Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2014184   | 10.4 | 4 |
| 18 | Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 21493-21500 | 11.5 | 4 |
| 17 | Transverse Transperineal Repair of a Pessary-induced Mid-rectovaginal Fistula. <i>Journal of Pelvic Medicine &amp; Surgery</i> , <b>2008</b> , 14, 199-201   |      | 4 |
| 16 | Resilience: a mediator of the negative effects of pandemic-related stress on women's mental health in the USA. <i>Archives of Women's Mental Health</i> , <b>2021</b> ,  | 5    | 4 |
| 15 | The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 3985-4000  | 10.1 | 4 |
| 14 | Utility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients. <i>Gynecologic Oncology</i> , <b>2012</b> , 127, S5-S6  | 4.9  | 3 |
| 13 | Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome. <i>Gene</i> , <b>2004</b> , 341, 189-97  | 3.8  | 2 |
| 12 | Downregulation of a Mitogen-Activated Protein Kinase Signaling Pathway in the Placentas of Women With Preeclampsia. <i>Obstetrics and Gynecology</i> , <b>2000</b> , 96, 582-587   | 4.9  | 2 |
| 11 | RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. <i>Methods in Molecular Medicine</i> , <b>2001</b> , 39, 299-306   |      | 1 |
| 10 | Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer. <i>Cancer Research</i> , <b>2021</b> ,  | 10.1 | 1 |
| 9  | A streamlined mass spectrometry-based proteomics workflow for large scale FFPE tissue analysis   |      | 1 |
| 8  | The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment. <i>Cancers</i> , <b>2021</b> , 13,  | 6.6  | 1 |
| 7  | The balance between toxic versus nontoxic microRNAs determines platinum sensitivity in ovarian cancer  |      | 1 |
| 6  | Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 130-133  | 4.9  | 1 |
| 5  | Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer.. <i>JCO Oncology Practice</i> , <b>2022</b> , OP2100514              | 2.3  | 0 |
| 4  | High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas.. <i>Gynecologic Oncology Reports</i> , <b>2022</b> , 41, 100987   | 1.3  | 0 |
| 3  | A special key for unlocking the door to targeted therapies of breast cancer. <i>Scientific World Journal, The</i> , <b>2008</b> , 8, 905-8   | 2.2  |   |

- 2 Metabolic reprogramming of the stromal epigenome in ovarian cancer metastasis. *FASEB Journal*, **2019**, 33, lb240 0.9
- 1 Healthy food for trainees: a call to action. *Postgraduate Medical Journal*, **2021**, 97, 740-741 2